Human Continuum Closes Over $5 Million in Seed Round Funding to Support the Development of its Integrated Exosome-Based Therapeutic Longevity Platform

Jupiter, F.L., June 11, 2026 (GLOBE NEWSWIRE) — Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has closed a $5.13 million seed financing to advance development of its exosome-based therapeutics and diagnostics platform focused on longevity and regenerative medicine.